Article Text

Download PDFPDF

4CPS-140 Experience of using palbociclib, ribociclib and abemaciclib in a tertiary hospital
Free
  1. L Gutiérrez Lucena,
  2. MD Córdoba Sotomayor,
  3. R Contreras Collado,
  4. B Oya Alvarez De Morales,
  5. P López López
  1. Hospitalary Complex Of Jaén, Hospital Pharmacy, Jaén, Spain

Abstract

Background and Importance The cyclin-dependent kinase 4 and 6 (CPKi) inhibitor drugs palbociclib, ribociclib and abemaciclib, in combination with hormone therapy have been shown to improve progression-free survival, and in some cases, overall survival, in women with HER2-positive, hormone receptor-positive or locally advanced breast cancer.

Aim and Objectives Evaluate dose adjustment due to safety data in routine clinical practice in women with metastatic breast cancer.

Material and Methods Observational, descriptive and retrospective study including women treated with palbociclib, ribociclib and abemaciclib in combination with hormone therapy between January 2018 and December 2021.

Patients with active CPKi treatment were selected. Data collected by reviewing digital medical records. These data were: age, initial dose, whether they received CPKi as the first line of treatment, dose reduction, treatment interruption, and months of treatment during the study follow-up period.

Conclusion and Relevance Ribociclib is the CPKi most commonly prescribed as the first-line. In the abemaciclib group, more patients maintained initial dose, and fewer patients reduced the starting dose compared to palbociclib and ribociclib groups, but the small population of our cohort does not allow to assume this results. However, there were more interruptions of treatments in this group.

Conflict of Interest No conflict of interest.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.